Skip to main content
. 2023 Feb 21;14:1135516. doi: 10.3389/fphar.2023.1135516

FIGURE 2.

FIGURE 2

Deteriorative effects of olanzapine on blood lipid profiles and body weight maintenance and the rescuing effects of vitamin D co-treatment from the JMDC insurance claims. The data of pre-prescription and post-prescription periods were collected from the nearest test data before or after the olanzapine prescription within 1 year. Background characteristics were matched between groups (n = 20) as shown in Table 2. (A–C) The annual blood test results from patients included in JMDC were extracted. (A) Serum concentrations of triglycerides, (B) low-density lipoprotein (LDL) cholesterol, and (C) high-density lipoprotein (HDL) cholesterol were expressed in units of mg/dL. (D,E) The annual body weights, heights, and waist circumferences included in the JMDC were extracted. (D) Body mass index (BMI) is calculated from body weights and heights and (E) waist circumferences were obtained by direct measurement. (F) the level of HbA1c expressed in units of percentage of blood. Data are shown as means ± SEM. *p < 0.05; a paired t-test of the pre-prescription period against the post-prescription period. # p < 0.05, ## p < 0.01; an unpaired two-tailed t-test with Welch’s correction between the group with and without vitamin D supplementation.